Severe hypomagnesaemia with tetany following ESHAP protocol by Majumdar, Gautam
BioMed  Central
Page 1 of 2
(page number not for citation purposes)
BMC Blood Disorders
BMC Blood Disorders  2002,  2 Case report
Severe hypomagnesaemia with tetany following ESHAP protocol
Gautam Majumdar
Address: FRCPath Consultant Haematologist Doncaster Royal Infirmary Thorne Road Doncaster, DN2 5LY United Kingdom
E-mail: gautam.majumdar@dbh.nhs.uk
Abstract
Background:  One patient with B-cell Non-Hodgkin's Lymphoma developed severe
hypomagnesaemia and tetany 15 days after the first course of treatment with ESHAP protocol. This
prompted a careful look at the incidence and severity of hypomagnesaemia during treatment with
this combination chemotherapy.
Method: This patient and two further patients having the same treatment were monitored for
hypomagnesaemia throughout their treatment period.
Result:  All three patients developed significant hypomagnesaemia requiring intravenous
magnesium infusion in the second and third weeks after treatment though not after every course
of chemotherapy.
Conclusions: ESHAP protocol is often associated with significant hypomagnesaemia two to three
weeks after treatment. Therefore, serum magnesium level should be monitored throughout the
treatment period.
Background
ESHAP protocol [1] is an effective second line treatment
for Non-Hodgkin's Lymphoma (NHL). This combination
includes etoposide, methyl prednisolone, cytarabine and
cisplatin. As cisplatin is known to cause hypomagnesae-
mia the protocol included daily monitoring of serum
magnesium from day 1 to 8 and daily infusion of 10
mmol of magnesium intravenously during the treatment
(days 1 to 5) period.
A 56 year old female with low-grade B-cell NHL proved re-
fractory to chlorambucil and CIOP (cyclophosphamide,
idarubicin, vincristine and prednisolone) combination
and was started on ESHAP protocol. During the first
course of treatment her serum magnesium remained with-
in the normal range (750 to 900 µmol/l) and on day 8 the
level was 680 µmol/l, slightly below the normal range.
On the day 15 (10 days after completion of treatment) she
presented with extreme prostration and tetany involving
both hands. Her full blood count, renal function, liver
function and serum calcium were normal. Serum magne-
sium was 313 µmol/l. She was given 10 mmol of magne-
sium by IV infusion for 3 successive days. After the first
infusion all her symptoms disappeared and her serum
magnesium level returned to normal after 3 days. Howev-
er, her serum magnesium level dropped to 460 µmol/l on
the day 21 when she required another infusion of magne-
sium 10 mmol. Thereafter, her serum magnesium level re-
mained within the normal range until the next course of
chemotherapy. This episode prompted monitoring of the
serum magnesium level of the patients undergoing treat-
ment with ESHAP protocol throughout their treatment
period.
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Method
Serum magnesium level was assayed twice weekly for
three patients who were treated with ESHAP protocol for
refractory NHL. Two patients received 4 courses and an-
other patient received 3 courses of ESHAP at 4 weekly in-
tervals (total 11 courses). None of the patients had any
renal impairment and were not on any other potentially
nephrotoxic drugs. The serum magnesium levels were
normal in all three patients prior to each course of chem-
otherapy.
Result
During these 11 courses of treatment, significant hy-
pomagnesaemia (< 500 µmol/l) was observed after 7
courses, once in the second week and the others in the
third week from the starting of the most recent course of
chemotherapy. In six of these episodes serum magnesium
level fell below 400 µmol/l and on these occasions the pa-
tients complained of general weakness, malaise and list-
lessness. Carpopedal spasm was observed on two
occasions in the same patient when serum magnesium
level fell to 313 and 271 µmol/l. Each time the serum
magnesium level fell below 500 µmol/l, patients were
treated with IV infusion of magnesium 10 mmol daily for
3 days which promptly corrected the hypomagnesaemia.
On 3 occasions further magnesium infusions were needed
at the end of the third week to keep serum magnesium lev-
el at a safe level (>500 µmol/l). Following the 4 remaining
courses of ESHAP mild hypomagnesaemia was noted in
the second and the third weeks after chemotherapy but
the serum magnesium level returned to normal in the
fourth week without any therapeutic intervention.
Discussion
Hypomagnesaemia is a known complication of cisplatin
therapy though it is usually asymptomatic. Hypomagne-
saemia often develops in the first 2 weeks after cisplatin
therapy when the renal tubular damage is most severe. In
these 3 patients hypomagnesaemia developed later than
usual probably because of magnesium supplementation
during the treatment. However, the degree of hypomagne-
saemia was more severe than expected and on two occa-
sions caused carpopedal spasm. On 4 other occasions
hypomagnesaemia was associated with non-specific
symptoms which responded to magnesium infusion.
More serious manifestations of hypomagnesaemia were
prevented by magnesium infusion during these episodes.
One of these patients, not the one who had tetany, was on
long-term oral frusemide therapy for pedal oedema which
might have contributed to developing hypomagnesaemia
but the other two patients were not on any other drug
which might have aggravated the effect of cisplatin.
Conclusion
ESHAP protocol may induce severe and late hypomagne-
saemia. Patients receiving ESHAP protocol should have
their serum magnesium level monitored twice weekly
throughout the course of the treatment as some of these
patients would require magnesium supplementation in
the second and third weeks after chemotherapy.
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